1. Yarbro CH, Wujcik D, Gobel BH. Cancer Nursing: Principles and Practice. 8th ed. Boston, MA: Jones and Bartlett Publishers; 2016.
2. Katzel JA, Hari P, Vesote DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57(5):301-318.
3. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.
4. Shane E. Etiology of Hypercalcemia. Available at https://www.uptodate.com/contents/etiology-of-hypercalcemia. Last accessed February 6, 2024.
6. Durie BGM. Multiple Myeloma: Cancer of the Bone Marrow. Concise Review of Relapsed and Refractory Myeloma: 2023 Edition. Available at https://issuu.com/international-myeloma-foundation/docs/concise-review-en? Last accessed February 6, 2024.
7. Bertanha F, Boufelli G, de Camargo OP, et al. Oncologic progression of bone plasmacytomas to multiple myeloma. Clinics. 2006;61(2):139-146.
9. Doss DS. Advances in oral therapy in the treatment of multiple myeloma. Clin J Oncol Nurs. 2006;10(4):514-520.
10. Tariman JD. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Clin J Oncol Nurs. 2007;11(4):569-574.
11. International Myeloma Foundation. [Archive]. Novel Therapies for Multiple Myeloma Patients. Available at https://www.myeloma.org/videos/novel-therapies-multiple-myeloma-patients. Last accessed February 6, 2024.
12. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
13. American Cancer Society. Getting a Stem Cell or Bone Marrow Transplant. Available at https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/stem-cell-transplant/process.html. Last accessed February 6, 2024.
14. American Cancer Society. Stem Cell Transplant for Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/treating/stem-cell-transplant.html. Last accessed February 6, 2024.
15. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
16. Shah D. Multiple Myeloma: Clinical Presentation. Available at https://emedicine.medscape.com/article/204369-clinical. Last accessed February 6, 2024.
19. Laubach JP. Multiple Myeloma: Clinical Features, Laboratory Manifestations, and Diagnosis. Available at https://www.uptodate.com/contents/multiple-myeloma-clinical-features-laboratory-manifestations-and-diagnosis. Last accessed February 6, 2024.
20. National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ). Available at https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq. Last accessed February 6, 2024.
21. Zehnder JL. Bone Marrow Aspiration and Biopsy: Indications and Technique. Available at https://www.uptodate.com/contents/bone-marrow-aspiration-and-biopsy-indications-and-technique. Last accessed February 6, 2024.
22. Tariman JD, Estella SM. The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing. Oncol Nurs Forum. 2005;32(6):E127-E138.
23. American Cancer Society. Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma.html. Last accessed February 6, 2024.
24. American Cancer Society. Cancer Facts and Figures 2024. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf. Last accessed February 6, 2024.
25. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. Available at https://seer.cancer.gov/statfacts/html/mulmy.html. Last accessed February 6, 2024.
26. Shah D. Multiple Myeloma: Etiology. Available at https://emedicine.medscape.com/article/204369-overview#a4. Last accessed February 6, 2024.
27. Barrick MC, Mitchell SA. Multiple myeloma: recent advances for this common plasma cell disorder. AJN. 2001;101:6-12.
28. Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15(3):301-304.
29. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines, 2013. Mayo Clin Proc. 2013;88(4):360-376.
30. Rajkumar SV. Multiple Myeloma: Pathobiology. Available at https://www.uptodate.com/contents/multiple-myeloma-pathobiology. Last accessed February 6, 2024.
31. Ballas ZK. Structure of Immunoglobulins. Available at https://www.uptodate.com/contents/structure-of-immunoglobulins. Last accessed February 6, 2024.
32. Manis JP. Overview of Therapeutic Monoclonal Antibodies. Available at https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies. Last accessed February 6, 2024.
33. Chen K, Cerutti A. The function and regulation of immunoglobulin D. Curr Opin Immunol. 2011;23(3):345-352.
34. Gutzeit C, Chen K, Cerutti A. The enigmatic function of IgD: some answers at last. Eur J Immunol. 2018;48(7):1101-1113.
36. Manolagas SC. Normal Skeletal Development and Regulation of Bone Formation and Resorption. Available at https://www.uptodate.com/contents/normal-skeletal-development-and-regulation-of-bone-formation-and-resorption. Last accessed February 6, 2024.
38. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003;4(5):284-292.
39. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Am J Health Syst Pharm. 2001;58(Suppl 3):S16-S20.
40. Osowoski M. Spinal cord compression: an obstructive oncologic emergency. Top Adv Pract Nurs eJournal. 2002;2(4):1-8.
42. Robiana DF, Colon K, Ely S, Ely S, Chesi M, Bergsagel PL. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematological Oncology. 2007;25(5):16-20.
43. Shah D. Multiple Myeloma: Workup. Available at https://emedicine.medscape.com/article/204369-workup. Last accessed February 6, 2024.
44. Luukkonen J, Hilli M, Nakamura M, et al. Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. Histochem Cell Biol. 2019;151(6):475-487.
45. Si J, Wang C, Zhang D, Wang B, Zhou Y. Osteopontin in bone metabolism and bone disease. Med Sci Monit. 2020;26:e919159.
46. Roodman GD. Mechanisms of Bone Metastases. Available at https://www.uptodate.com/contents/mechanisms-of-bone-metastases. Last accessed February 6, 2024.
47. Chantry A, Kazmi M, Barrington S, et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017;178(3):380-393.
48. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Oncology. 2017;18(4):e206-e217.
49. Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657-664.
50. Mulligan ME. Multiple Myelomma Imaging. Available at https://emedicine.medscape.com/article/391742-overview#a4. Last accessed February 6, 2024.
51. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121(6):884-892.
52. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma: Version 2.2024. Available at https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Last accessed February 6, 2024.
53. American Cancer Society. How is Chronic Lymphocitic Leukemia Diagnosed? Available at https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/detection-diagnosis-staging/how-diagnosed.html. Last accessed February 6, 2024.
54. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-2221.
55. Chng WJ, Santana-Dávila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807-813.
56. Avet-Louseau H, Daviet A, Sauner S, Bataille R Intergroupe Francophone du Myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol. 2000;111:1116-1117.
57. Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res. 2014;20(4):804-813.
58. Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262.
59. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Del(17p) in Myeloid Malignancies. Available at https://atlasgeneticsoncology.org/haematological/1142/del(17p)-in-myeloid-malignancies. Last accessed February 6, 2024.
60. Testing.Com. Bone Marrow Aspiration and Biopsy. Available at https://www.testing.com/tests/bone-marrow-aspiration-and-biopsy/. Last accessed February 6, 2024.
61. Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol. 2011;12:617-619.
62. Parameswaran NH, Mei-Jie Z, Vivek R, et al. Is the International Staging System superior to the Durie Salmon Staging System? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009;23(8):1528-1534.
63. D'Agostino M, Cairms DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406-3418.
64. ASCO Publications. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Available at https://ascopubs.org/doi/10.1200/jco.2015.61.2267. Last accessed February 6, 2024.
65. American Cancer Society. Multiple Myeloma Stages. Available at https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/staging.html. Last accessed February 6, 2024.
66. Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment. Mayo Clinic Proc. 2006;81(6): 835-848.
67. American Cancer Society. Survival Rates by Stage for Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/survival-rates.html. Last accessed February 6, 2024.
68. Rajkumar SV. Upfront therapy for myeloma: tailoring therapy across the disease spectrum. Am Soc Clin Oncol Educ Book. 2012:508-514.
69. mSMART Treatment Guidelines: Multiple Myeloma. Available at https://www.msmart.org/mm-treatment-guidelines. Last accessed February 6, 2024.
70. ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale. Available at https://ecog-acrin.org/resources/ecog-performance-status. Last accessed February 6, 2024.
71. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976-4984.
72. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade) in the treatment of multiple myeloma. Ther Clin Risk Manag. 2006;2(3):271-279.
73. Shah D. Multiple Myeloma: Treatment and Management. Available at https://emedicine.medscape.com/article/204369-treatment. Last accessed February 6, 2024.
74. International Myeloma Foundation. Role of Transplant. Available at https://www.myeloma.org/autologous-stem-cell-transplant. Last accessed February 6, 2024.
75. LexiComp Online. Available at https://online.lexi.com/action/login. Last accessed February 6, 2024.
76. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
77. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. Blood. 2007;110:77
78. Rajkumar SV, Jacobus S, Callander N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006;108:799.
79. U.S. Food and Drug Administration. FDA Approves Daratumumab and Hyaluronidase-Fihj for Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma. Last accessed February 6, 2024.
80. Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology. 2007;21(12):1503-1508.
81. Chu E, DeVita VT (eds). Physicians' Cancer Chemotherapy Drug Manual. 18th ed. Burlington, MA: Jones and Bartlett Publishers; 2018.
82. Rodriguez AL, Tariman JD, Enecio T, Estrella SM. The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing. Clin J Oncol Nurs. 2007;11(4):569-589.
83. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464-2472.
85. Xu XL, Gou WL, Wang AY, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med. 2013;11:303.
86. Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology. 2021;22(3):E119-E130.
87. Mangan P, Bernstein S. Managing Patients with Multiple Myeloma: Where are We Now? Highlights from a Satellite Symposium Held during the 32nd Annual Congress of the Oncology Nursing Society. Pittsburg, PA: Oncology Nursing Society; 2007.
88. American Association of Oral and Maxillofacial Surgeons. Position Paper: Medication-Related Osteonecrosis of the Jaw—2022 Update. Available at https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf. Last accessed February 6, 2024.
89. Goldman DA. Thalidomide use: past history and current implications for practice. Oncol Nurs Forum. 2001;28(3):471-477.
90. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clinic Proc. 2002;77(8):813-822.
91. Rao KV. Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm. 2007;64(17):1799-1807.
92. Dimopoulous MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21(23):4444-4454.
93. Ghobrial J, Ghobrial IM, Mitsiades C, et al. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology. 2007;21(7):785-792.
94. Tariman JD. Thalidomide: current therapeutic uses and management of its toxicities. Clin J Oncol Nurs. 2003;7(2):143-147.
96. MedlinePlus. Thalidomide. Available at https://medlineplus.gov/druginfo/meds/a699032.html. Last accessed February 6, 2024.
97. Weber D. Thalidomide and its derivatives: new promises for multiple myeloma. Cancer Control. 2003;10(5):375-383.
98. National Cancer Institute. Thalidomide. Available at https://www.cancer.gov/about-cancer/treatment/drugs/thalidomide. Last accessed February 6, 2024.
99. Zaidi AA, Vesote DH. Multiple myeloma: an old disease with new hope for the future. CA Cancer J Clin. 2001;51(5):273-285.
100. U.S. Food and Drug Administration. Lenalidomide (Revlimid). Available at https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid. Last accessed February 6, 2024.
101. International Myeloma Foundation. Revlimid (Lenalidomide). Available at https://www.myeloma.org/revlimid-lenalidomide. Last accessed February 6, 2024.
102. Revlimid. Patient Resources. Available at https://www.lenalidomiderems.com/index.html. Last accessed February 6, 2024.
103. U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-cancer-drug-revlimid-lenalidomide-and-risk. Last accessed February 6, 2024.
104. Mitchell BS. The proteasome—an emerging therapeutic target in cancer. N Engl J Med. 2003;26(384):2597-2599.
105. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004;8(5):473-480.
106. Reece D, Kouroukis T, Haynes AI, Imrie K. Bortezomib in Multiple Myeloma and Lymphoma. Toronto: Cancer Care Ontario; 2008.
107. Grammatico S, Cesini L, Petrucci MT. Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat Cancer. 2016;6:37-47.
108. National Cancer Institute. FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple Myeloma. Available at https://www.cancer.gov/news-events/cancer-currents-blog/2015/carfilzomib-myeloma. Last accessed February 6, 2024.
109. National Cancer Institute. Pomalidomide. Available at https://www.cancer.gov/about-cancer/treatment/drugs/pomalidomide. Last accessed February 6, 2024.
110. National Cancer Institute. FDA Approves Panobinosta for Some Patients with Multiple Myeloma. Available at https://www.cancer.gov/news-events/cancer-currents-blog/2015/fda-approves-panobinostat#. Last accessed February 6, 2024.
111. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
112. U.S. Food and Drug Administration. FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma. Last accessed February 6, 2024.
113. U.S. Food and Drug Administration. FDA Approves Isatuximab-irfc for Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma. Last accessed February 6, 2024.
114. U.S. Food and Drug Administration. FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma. Last accessed February 6, 2024.
115. U.S. Food and Drug Administration. FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Last accessed February 6, 2024.
116. U.S. Food and Drug Administration. FDA Granta Accelerated Approval to Elranatamab-BCMM for Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma. Last accessed February 6, 2024.
117. U.S. Food and Drug Administration. FDA Approves Teclistamab-cqyv for Relased or Refractory Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Last accessed February 6, 2024.
118. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma. Last accessed February 6, 2024.
119. U.S. Food and Drug Administration. FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma. Last accessed February 6, 2024.
120. Rajkumar SV. Multiple Myeloma: Use of Autologous Hematopoietic Cell Transplantation. Available at https://www.uptodate.com/contents/multiple-myeloma-use-of-autologous-hematopoietic-cell-transplantation. Last accessed February 6, 2024.
121. Imrie K, Rumble RB, Crump M, Advisory Panel on Bone Marrow and Stem Cell Transplantation, Hematology Disease Site Group. Stem Cell Transplantation in Adults: Recommendations. Toronto: Cancer Care Ontario Program in Evidence-Based Care; 2009.
122. Negrin RS. Patient Education: Hematopoietic Cell Transplantation (Bone Marrow Transplantation). Available at https://www.uptodate.com/contents/hematopoietic-cell-transplantation-bone-marrow-transplantation-beyond-the-basics. Last accessed February 6, 2024.
123. Perumbeti A. Hematopoietic Stem Cell Transplantation. Available at https://emedicine.medscape.com/article/208954-overview. Last accessed February 6, 2024.
124. Cleveland Clinic. Graft vs. Host Disease. Available at https://my.clevelandclinic.org/health/diseases/10255-graft-vs-host-disease-an-overview-in-bone-marrow-transplant. Last accessed February 6, 2024.
125. NMDP. Be the Match Registry Recruitment and Availability. Available at https://bethematch.org/about-us/how-we-help-patients/be-the-match-registry/. Last accessed February 6, 2024.
126. Be the Match. HLA Matching Guidelines for Selecting Unrelated Donors and CBUs for HCT. Available at https://bethematchclinical.org/resources-and-education/education-courses-and-events/cme-activities/applying-matching-guidelines/. Last accessed February 6, 2024.
127. Leukemia and Lymphoma Society. Reduced-Intensity Allogeneic Stem Cell Transplantation. Available at https://www.lls.org/treatment/types-treatment/stem-cell-transplantation/reduced-intensity-allogeneic-stem-cell. Last accessed February 6, 2024.
128. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 2005;36(11):963-969.
129. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA. A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009;15(1):83-91.
130. Björkstrand B, Iocabelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous translantation in myeloma: long-term follow-up. J Clin Oncol. 2010;29(22):7312.
132. Paul B, Lipe B, Ocio EM, Usmani SZ. Induction therapy for newly diagnosed multiple myeloma. Am Soc Clin Oncol Educ Book. 2019;38(39).
133. Lytvynova O, Jwayyed J, Hameed M, et al. Evidence-based recommendations for induction treatment of newly diagnosed transplant-eligible multiple myeloma patients: a scoping review. Blood. 2023;142(Suppl 1):6590.
134. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006;107(1):397-403.
135. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629.
136. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.
137. Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;CD010816.
138. Reiffers J, Goldman JM, Armitage JO (eds). Blood Stem Cell Transplantation. London: Martin Dunitz Ltd; 1998.
139. Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilization for autologous transplantation in people with malignant lymphoma or multiple myeloma. Cochrane Database Syst Rev. 2015;(10):CD010615.
140. Salvino MA, Ruiz J. Hematopoietic progenitor cell mobilization for autologous transplantation: a literature review. Rev Bras Hematol Hemoter. 2016;38(1):28-36.
141. The ASCO Post Staff. FDA Approves New Multiple Myeloma Combination Therapy. Available at https://ascopost.com/news/september-2023/fda-approves-new-multiple-myeloma-combination-therapy/. Last accessed February 6, 2024.
142. National Cancer Institute. Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma. Available at https://www.cancer.gov/news-events/cancer-currents-blog/2023/motixafortide-multiple-myeloma-stem-cell-transplant. Last accessed February 6, 2024.
143. Blanes M, Lahuerta JJ, González JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19(1):69-74.
144. El-Ghammaz AMS, Abdelwahed E. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis. Ann Hematol. 2016;95(8):1315-1321.
145. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
146. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
147. International Myeloma Foundation. Understanding Stem Cell Transplant. North Hollywood, CA: International Myeloma Foundation; 2007.
148. Merck Manual. Multiple Myeloma. Available at https://www.merckmanuals.com/professional/hematology-and-oncology/plasma-cell-disorders/multiple-myeloma. Last accessed February 6, 2024.
149. Merck Manual. Hypercalcemia. Available at https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypercalcemia. Last accessed February 6, 2024.
150. National Collaborating Centre for Cancer. Metastatic Spinal Cord Compression: Diagnosis and Management of Adults at Risk of and with Metastatic Spinal Cord Compression. London: National Institute for Health and Clinical Excellence; 2008.
151. Flounders JA, Ott BB. Oncology emergency modules: spinal cord compression. Oncol Nurs Forum. 2003;30(1):E17-E23.
152. Osowski M. Spinal cord compression: an obstructive oncologic emergency. Topics Adv Pract Nurse J. 2002;2(4).
153. Dugas AF, Lucas JM, Edlow JA. Diagnosis of spinal cord compression in nontrauma patients in the emergency department. Acad Emerg Med. 2011;18(7):719-725.
154. Kyriakou C, Molloy S, Vrionis F, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J. 2019;9(3):27.
156. Papanastassiou ID, Vrionis FD. Is early vertebroplasty/kyphoplasty justified in multiple myeloma given the rapid vertebral fracture progression. Spine J. 2016;16(7):833-834.
157. Malhotra K, Butler JS, Yu HM, et al. Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. BMC Cancer. 2016;16:444.
158. Padovani B, Kasriel O, Brunner P, Peretti-Viton P. Pulmonary embolism caused by acrylic cement: a rare complication of percutaneous vertebroplasty. Am J Neuroradiol. 1999;20:375-377.
159. Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature. Spine. 2008;8(3):488-497.
160. Rajkumar SV, Kaplan AA, Leung N. Kidney Disease in Multiple Myeloma and Other Monoclonal Gammopathies: Treatment and Prognosis. Available at https://www.uptodate.com/contents/kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies-treatment-and-prognosis. Last accessed February 6, 2024.
161. Rajkumar SV. Monoclonal Immunoglobulin Deposition Disease. Available at https://www.uptodate.com/contents/monoclonal-immunoglobulin-deposition-disease. Last accessed February 6, 2024.
162. Leung N, Appel GB, Rajkumar SV. Kidney Disease in Multiple Myeloma and Other Monoclonal Gammopathies: Etiology and Evaluation. Available at https://www.uptodate.com/contents/kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies-etiology-and-evaluation. Last accessed February 6, 2024.
163. Parmar MS. Light Chain-Associated Renal Disorders. Available at https://emedicine.medscape.com/article/244082-overview. Last accessed February 6, 2024.
164. Wu TH, Li KJ, Yu CL, Tsai CY. Tamm-Horsfall protein is a potent immunomodulatory molecule and a disease biomarker in the urinary system. Molecules. 2018;23(1):200.
165. Patras KA, Coady A, Olson J, et al. Tamm-Horsfall glycoprotein engages human Siglec-9 to modulate neutrophil activation in the urinary tract. Immunol Cell Biol. 2017;95(10):960-965.
166. Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl. 2010;21(1):63-68.
167. Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network. GIMEMA. 2010;84(3):223-228.
168. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9(4):302-306.
1. National Collaborating Centre for Cancer. Myeloma: Diagnosis and Management. London: National Institute for Health and Care Excellence; 2018. Available at https://www.nice.org.uk/guidance/ng35. Last accessed March 14, 2024.
2. Shek-Man Lo S, Ryu S, Chang EL, et al. ACR Appropriateness Criteria: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis. Reston, VA: American College of Radiology; 2014. Available at https://acsearch.acr.org/docs/3091670/Narrative. Last accessed March 14, 2024.
3. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2019. Available at https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPGFinal5082142020.pdf. Last accessed March 14, 2024.
Mention of commercial products does not indicate endorsement.